Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Review Source Type: research

Related Links:

Authors: Li AA, Ahmed A, Kim D Abstract Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and encompasses a spectrum of pathology from simple steatosis to inflammation and significant fibrosis that leads to cirrhosis. NAFLD and its comorbid conditions extend well beyond the liver. It is a multisystemic clinical disease entity with extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, chronic kidney disease, hypothyroidism, polycystic ovarian syndrome, and psoriasis. Indeed, the most common causes of mortality in subjects with NAFLD are cardiovascular disease, f...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Authors: Tanner C, Wang G, Liu N, Andrikopoulos S, Zajac JD, Ekinci EI Abstract ■Metformin is recommended as first-line therapy for type 2 diabetes because of its safety, low cost and potential cardiovascular benefits. ■The use of metformin was previously restricted in people with chronic kidney disease (CKD) - a condition that commonly coexists with diabetes - due to concerns over drug accumulation and metformin-associated lactic acidosis. ■There are limited data from observational studies and small randomised controlled trials to suggest that metformin, independent of its antihyperglycaemic effects, may be ...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
CONCLUSION: The association of normoalbuminuria is common in DKD. The decline of renal function is slower in normoalbuminuria; however, the risk factors, clinical progression, and renal pathology in these patients need to be further explored.
. PMID: 31198168 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: Tags: Clin Nephrol Source Type: research
Guidelines used by GPs to monitor chronic diseases are based on expert opinion rather than evidence, according to a review of the guidelines by National Institute for Health Research (NIHR) researchers at the University of Bristol. The review, published today [Thursday 13 June] in the British Medical Journal, looked at guidelines for chronic kidney disease, high blood pressure and type 2 diabetes, which are monitored through a range of tests in GP surgeries.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research, International; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Abstract While rates of ischemic complications in type 2 diabetes mellitus seem to be declining, some of the most feared and costly complications, namely end-stage kidney disease (ESKD), heart failure, and lower limb amputations, remain on the rise. Herein, we discuss how the results from the Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE) trial may change this calculus.1 The development of chronic kidney disease (CKD) in type 2 diabetes mellitus marks the beginning of a sharp increase in cardio-renal complications.2 Indeed, in ty...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions®
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
Publication date: Available online 7 June 2019Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Ferdinando Carlo Sasso, Pia Clara Pafundi, Aldo Gelso, Valeria Bono, Ciro Costagliola, Raffaele Marfella, Celestino Sardu, Luca Rinaldi, Raffaele Galiero, Carlo Acierno, Alfredo Caturano, Chiara de Sio, Luca De Nicola, Teresa Salvatore, Riccardo Nevola, Luigi Elio Adinolfi, Roberto Minutolo, NO BLIND Study GroupAbstractBackground and AimsRecently the albuminocentric view of diabetic kidney disease (DKD) in type 2 diabetes (T2DM) has been changing. Therefore, the relationship between diabetic retinopathy (DR) an...
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Conclusions: Bard treatment results in significant decreases in serum magnesium that are not associated with changes in intracellular and urinary magnesium levels, indicating that magnesium decreases are not due to renal magnesium wasting or total body magnesium depletion. Importantly, the decreases in serum magnesium with Bard are not associated with adverse effects on QT interval.Cardiorenal Med
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research
Conclusions: The data we present here support the need to implement routine kidney biopsies in normoalbuminuric diabetic subjects in the early stages of CKD. Such strategy may help to improve risk stratification in diabetic patients and guide therapeutic decisions during the early stages of the disease.Am J Nephrol
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Urology & Nephrology